Richa Gandhi


I am a final-year EPSRC-funded PhD researcher enrolled in the Centre for Doctoral Training in Tissue Engineering and Regenerative Medicine (CDT TERM). My current work involves using molecular imaging techniques to investigate aspects of the molecular evolution of abdominal aortic aneurysms. This work has applications in facilitating early diagnosis and improving personalised medicine. My academic career thus far has helped me develop fundamental research skills and experience to be applied in my doctoral project and beyond.

Previously, I have studied extensively about the deterioration of tissues and organs in the context of neurodegenerative diseases and cancers. The CDT TERM interdisciplinary programme has provided me with the opportunity to place a positive spin on my previous knowledge owing to my research project's fundamental concepts of early disease detection and individualised therapeutics to improve patient quality of life.

Prior to this, I completed my Honours BSc in Neuroscience at the University of Toronto in Canada, after which I moved to England to complete my MSc in Cancer Studies at Oxford Brookes University. My current experience includes more than 2 years of working as an Editor for Editage, in addition to 18 months of previously working as a Copyeditor for the Imperial College Press, to edit and prepare manuscripts for publication in scientific and medical journals. At the University of Leeds, I am an Examination Invigilator and Biochemistry Laboratory Demonstrator. I was also the primary supervisor for an MSc Medical Imaging project that investigated the effect of radiotracer uptake value thresholds on PET image segmentation, and I have taken up some teaching opportunities in the School of Medicine and Health (Medical Imaging and Cancer; PET Imaging for Cardiovascular Applications).

Research interests

My current work is centred on molecular imaging to shed light on the molecular evolution of abdominal aortic aneurysms (AAA). This work involves implementing preclinical models of AAA to better understand the changes in cell proliferation associated with AAA progression using methodologies such as in vivo PET/CT imaging, ex vivo whole-organ gamma counting, and ex vivo autoradiography with novel radiotracers. These methodologies are further supported by immunohistochemical tissue staining, gel electrophoresis, and Western blotting techniques in my project. Once established, these non-invasive imaging technologies hold immense promise for early and precise diagnostic methods for effective patient stratification as well as personalised therapeutic approaches.


  • MSc Cancer Studies
  • Hons. BSc Neuroscience

Research groups and institutes

  • Institute of Medical and Biological Engineering